Biological and Pharmaceutical Bulletin · 2002 · 85 citations · 21 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular PharmacologyChemotherapy ResistanceEnzyme InhibitionMitochondrial DysfunctionAnticancer Drug ResistanceArtemisinin ResistanceDrug Resistance ModulationMitochondrial Membrane Potential CollapseMultidrug Resistance ModulationOvercoming Multidrug ResistanceTherapeutic Drug Resistance
Overcoming MDR (multidrug resistance) phenomena is a crucial aspect of cancer chemotherapy research. Artemisinin and its derivatives have been found to inhibit the proliferation of cancer cells in the microM range. They poorly inhibited the function of P-glycoprotein and did not inhibit the function of MRP1-protein. The concentrations required to inhibit by 50% the function of P-glycoprotein are 110+/-5 microM. Artemisinin, artesunate and dihydroartemisinin efficiently decreased the mitochondrial membrane potential, leading to a decrease in intracellular ATP in all cell lines tested: by 30 to 50% at 5 microM. Artemisinin, artesunate and dihydroartemisinin increased cytotoxicity of pirarubicin and doxorubicin in P-glycoprotein-overexpressing K562/adr, and in MRP1-overexpressing GLC4/adr, with the delta(0.5) ranging from 200 to 860 nM, but not in their corresponding drug-sensitive cell lines. In this range of concentrations these compounds did not decrease the function of P-glycoprotein, suggesting a mechanism by which the drugs did not reverse MDR phenomenon at the P-glycoprotein level but at the mitochondrial level.
21
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
CB Lozzio, BB Lozzio · Blood · 1975 · 2.8K citations
Medicine, Hematology, Oncology +14
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
CB Lozzio, BB Lozzio · Blood · 1975 · 2.3K citations · Full text
Medicine, Hematology, Oncology +14
Michael Müller, Coby Meijer, G J Zaman et al. · Proceedings of the National Academy of Sciences · 1994 · 622 citations · Full text
Medicine, Oncology, Pharmacology +17